Moreover, we demonstrated that key TSGs like CDCP1, PDLIM4, and TNFRSF12A may serve as therapeutic targets for AD, while TNFRSF12A and SFN are promising for GBM. This evidence concerns the gene PDLIM4 and glioblastoma.